GLP-1 weight-loss drugs may change what you crave, not just how much you eat
A prospective observational pilot study of 38 adults without diabetes found that three months of semaglutide or tirzepatide treatment was associated with an average weight loss of 7.2 kg, reduced food cravings, increased satiety, and improved self-reported hunger control. Most participants reported smaller meal portions, while some experienced changes in food preferences, although the study could…
Read original article on The Medical News →Related news
-
Childhood cancer cells shape-shift to spread without genetic mutations
United Kingdom
-
AI assesses what really matters to people in health care—well-being
United Kingdom
-
Early trial results suggest potential new treatment for stiff person syndrome
United Kingdom
-
US youths see nearly 4,000 food marketing messages on digital media each year
United Kingdom
-
A brief history of the food pyramid – and its many false starts
Australia
-
Fish Stocks Thrive Thanks to This Pink Seaweed and Locals Who Protected It
United Kingdom
-
It takes a neighborhood to keep kids active
United Kingdom
-
Two-year study will examine how gender-affirming hormone therapy affects energy use and blood vessel function
United Kingdom